bluebird bio (BLUE) Misses Q4 EPS by 10c

bluebird bio (NASDAQ: BLUE) reported Q4 EPS of ($0.67), $0.10 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.2 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• C.H. Robinson acquires DeSpir Logistics for $75 million